Judgment Day for Bayer: Supreme Court Ruling Looms Over New CFO and Pipeline Progress

Bayer shares vaulted 4.6% to €37.51 on Thursday, hitting a monthly high as investors placed their bets on a single binary catalyst: the US Supreme Court’s impending decision in the Durnell case. The ruling, expected later today, will determine whether a company can be held liable under state law when the federal EPA has already deemed a product safe. A victory for Bayer would effectively wipe out the vast majority of the roughly 65,000 outstanding glyphosate lawsuits; a defeat leaves the litigation wave intact.

The stock had already climbed 5.07% over the previous seven sessions, but Thursday’s surge — which briefly pushed the shares above their 50-day moving average of €37.92 before settling just beneath it — reflects the all-or-nothing nature of the gamble. UBS analyst Matthew Weston maintains a €52 price target, nearly 40% above the current level, calling the move a “hope trade with a high lever in either direction.”

New CFO, Old Financial Strains

Into this high-stakes environment steps Judith Hartmann, who took over as chief financial officer on June 1, succeeding Wolfgang Nickl upon his planned retirement. Hartmann brings turnaround experience from stints as CFO at Bertelsmann and deputy CEO at ENGIE, plus leadership roles at General Electric across the US, Europe and Brazil. She inherits a company bleeding cash: net outflows exceeded €2 billion in the first quarter of 2026, largely for PCB and glyphosate litigation payments. The dividend for the 2025 financial year has been slashed to €0.11 per share, while Bayer has halved its management layers and cut thousands of jobs.

Yet the balance sheet is not the only front in flux. The European Medicines Agency has validated Bayer’s marketing application for Asundexian, a Factor XIa inhibitor designed to prevent ischemic strokes. In the Phase III OCEANIC-STROKE trial, the drug cut the risk of recurrent stroke by 26% compared with placebo. It is the first regulatory submission of its drug class in Europe; China and the US have already granted priority review. A European decision is expected within 12 to 18 months.

Should investors sell immediately? Or is it worth buying Bayer?

Asundexian’s timing is critical because Xarelto, Bayer’s blockbuster anticoagulant, is losing patent protection. Xarelto revenue slumped a third last year to $2.6 billion, and the new drug is meant to fill that gap. For 2026, Bayer expects stronger contributions from its agriculture and consumer health divisions to offset weaker pharma earnings, targeting a broadly stable overall performance.

Extra Tailwinds from Brussels

Beyond the courtroom, Bayer’s crop science arm received a structural boost this week when the EU decided that foods produced with modern gene-editing techniques can be sold without special labelling. The regulatory shift strengthens a division that has been under pressure from glyphosate-related uncertainty and commodity cycles.

Meanwhile, the broader DAX showed deep sector divergence on Thursday, with Bayer and Heidelberg Materials leading gainers while SAP, Deutsche Telekom and Vonovia fell under interest-rate pressure. The European Central Bank raised all three benchmark rates by 25 basis points on June 11, pushing the deposit facility to 2.25%, and the Fed under new chair Kevin Warsh has pushed expectations for rate cuts further into 2027.

For Bayer, the immediate focus remains on the Supreme Court. As one analyst put it, the stock is a binary trade: everything or nothing. The shares closed the session at €37.51, still shy of the 50-day line, but the next few hours could determine whether the recent momentum has legs — or snaps.